Daunorubicin hydrochloride is a classic ADC payload intercalating DNA and inhibiting topoisomerase II, inducing apoptosis. It remains a valuable ADC cytotoxin for targeted hematologic and solid tumor therapies.
Structure of 23541-50-6
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
1 g | $439 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
NCT Number | Condition Or Disease | Phase | Start Date | Sponsor | Status |
---|---|---|---|---|---|
NCT01802333 | Acute Myeloid Leukemia | Phase 3 | 2018-12-19 | National Cancer Institute (NCI) | Completed |
NCT00085124 | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 3 | 2013-06-05 | National Cancer Institute (NCI) | Completed |
NCT00474006 | ACUTE MYELOGENOUS LEUKEMIA | Phase 3 | 2011-06-10 | Cooperative Study Group A for Hematology | Completed |
NCT01806571 | Untreated Adult Acute Myeloid Leukemia | Phase 2 | 2020-08-18 | Mayo Clinic | Completed |
NCT02971397 | Acute Myeloid Leukemia | Phase 2 | 2018-11-02 | Wake Forest University Health Sciences | Unknown Verified November 2018 by Wake Forest University Health Sciences. Recruitment status was Active, not recruiting |
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-01360 | Daunorubicin citrate | 1884557-85-0 | |
BADC-00042 | Daunorubicin | 20830-81-3 | |
BADC-00039 | Doxorubicin | 23214-92-8 | |
BADC-00685 | MCC-Modified Daunorubicinol | 721945-30-8 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.